We Announce our Role as Regulatory Advisor to Liberate Medical on their Emergency Use Authorization of VentFree™

Alira Health’s Regulatory practice supported the authorization of the emergency use of VentFree™ by FDA under the Emergency Use Authorization.

News
Published on:
May 6, 2020

FRAMINGHAM, MASSACHUSETTS – MAY 6, 2020 – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, supported Liberate Medical, a clinical/commercial-stage medical device company, in their Emergency Use Authorization from the Federal Drug Administration (FDA) for the VentFree™ Respiratory Muscle Stimulator. Alira Health’s Regulatory team, led by Alira Health’s Mary McNamara-Cullinane, Senior Vice President, Regulatory Affairs, provided guidance and regulatory support to Liberate Medical, including developing a regulatory pathway and submission, and liaising with the FDA throughout the emergency use approval process.

We are grateful to the FDA for recognizing the potential of VentFree™ and feel privileged to help patients on mechanical ventilation during the COVID-19 pandemic,” said Angus McLachlan PhD, co-founder and CEO of Liberate Medical. “We also thank the Alira Health team for their support in gaining this authorization for VentFree™.”

The VentFree™ Respiratory Muscle Stimulator is a non-invasive and breath-synchronized electrotherapy device that may reduce ventilation duration during the COVID-19 pandemic. Using proprietary, non-invasive neuromuscular electrical stimulation to contract the abdominal wall muscles in synchrony with exhalation during mechanical ventilation, VentFree™ enables treatment to begin from the early phase of mechanical ventilation and continue until the patient is successfully weaned.

We are proud to support the team at Liberate Medical in receiving this Emergency Use Authorization, and to help them more rapidly impact patient care during this challenging time,” said Mary McNamara-Cullinane. “Our Regulatory practice is currently working on several Emergency Use Authorization submissions, helping companies to quickly put lifesaving products into the hands of providers across the globe.

About Liberate Medical:

Liberate Medical is a clinical / commercial stage medical device company that develops neuromuscular electrical stimulation technology to improve the quality and reduce the cost of care for patients with pulmonary disorders.

To learn more about Alira Health

Contact us

Related news

Multimedia September 29, 2022
Regulatory Strategy for Registering Rare Disease Products in the EU
In this webinar we will focus on how to benefit, today and in the future, from the orphan drug program and build a regulatory strategy for successful rare disease product registration(...)
Drug Development Rare Disease Regulatory
Events September 7, 2022
MDIC Annual Patient Forum 2022
We are pleased to share that we will be joining as speakers MDIC Annual Patient Forum 2022 – a key platform for the discussion of how to transform patient engagement throughout the(...)
Clinical Trials MedTech Patient Engagement
Events August 31, 2022
BIOMEDevice 2022
We are excited to share that we will be joining BIOMEDevice 2022 as speakers! This event will bring engineers, business leaders, disruptive companies, and innovative thinkers from the(...)
Investor Relations Medical Devices MedTech
Multimedia August 29, 2022
Webinar Replay: Clinical Trial Management in MedTech & Working with CROs
As a MedTech company, understanding clinical trial management is critical, and working with CROs is part of the journey. Join the webinar to learn about this crucial topic.
Clinical Trial Management CRO MedTech
Events August 23, 2022
MedtechVision 2022
Join us at the MedtechWomen MedtechVision Conference, where we will be presenting a state of the Medtech Industry Report with an overview of the innovation and advancement and much more.
Diagnotics MedTech Patient Centricity
Publications August 4, 2022
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
MedTech Regulatory
Publications July 15, 2022
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.
Real-World Evidence Registry-based studies Regulatory RWE
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.